CHAU TON-THAT: Open Payments
NPI 1205902301 · WESTMINSTER, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,737 in 72 payments from 9 companies in 2025. Trend: 2023 $2,568 · 2024 $1,408 · 2025 $1,737
Food & beverage: $1,737
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 16 | $467 |
| Vanda Pharmaceuticals Inc. | 14 | $438 |
| Alkermes, Inc. | 18 | $333 |
| E.R. Squibb & Sons, L.L.C. | 9 | $201 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $155 |
| Axsome Therapeutics, Inc. | 2 | $52 |
| Lundbeck LLC | 1 | $32 |
| LivaNova USA, Inc. | 1 | $31 |
| Neurocrine BioSciences, Inc. | 1 | $28 |
Products named: HETLIOZ, ARISTADA, REXULTI, COBENFY, CAPLYTA, ABILIFY MAINTENA, ABILIFY ASIMTUFII, FANAPT.
Industry payments across CA — which companies pay providers there.
